Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography

被引:7
|
作者
Jemaa, Skander [1 ]
Ounadjela, Souhila [1 ]
Wang, Xiaoyong [1 ]
El-Galaly, Tarec C. [2 ,3 ,4 ,5 ]
Kostakoglu, Lale [6 ]
Knapp, Andrea [7 ]
Ku, Grace [1 ]
Musick, Lisa [1 ]
Sahin, Denis [7 ]
Wei, Michael C. [1 ]
Yin, Shen [1 ]
Bengtsson, Thomas [8 ]
De Crespigny, Alex [1 ]
Carano, Richard A. D. [1 ]
机构
[1] Genentech Inc, South San Francisco, CA 94080 USA
[2] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark
[3] Odense Univ Hosp, Dept Hematol, Hematol Res Unit, Odense, Denmark
[4] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[5] AI Sweden, Lund, Sweden
[6] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA
[7] F Hoffmann La Roche, Basel, Switzerland
[8] Univ Calif Berkeley, Dept Stat, Berkeley, CA USA
关键词
ARTIFICIAL-INTELLIGENCE; LUNG-CANCER; PET/CT; DLBCL; CONSENSUS; CRITERIA;
D O I
10.1200/JCO.23.01978
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Artificial intelligence can reduce the time used by physicians on radiological assessments. For F-18-fluorodeoxyglucose-avid lymphomas, obtaining complete metabolic response (CMR) by end of treatment is prognostic. METHODS Here, we present a deep learning-based algorithm for fully automated treatment response assessments according to the Lugano 2014 classification. The proposed four-stage method, trained on a multicountry clinical trial (ClinicalTrials.gov identifier: NCT01287741) and tested in three independent multicenter and multicountry test sets on different non-Hodgkin lymphoma subtypes and different lines of treatment (ClinicalTrials.gov identifiers NCT02257567, NCT02500407; 20% holdout in ClinicalTrials.gov identifier NCT01287741), outputs the detected lesions at baseline and follow-up to enable focused radiologist review. RESULTS The method's response assessment achieved high agreement with the adjudicated radiologic responses (eg, agreement for overall response assessment of 93%, 87%, and 85% in ClinicalTrials.gov identifiers NCT01287741, NCT02500407, and NCT02257567, respectively) similar to inter-radiologist agreement and was strongly prognostic of outcomes with a trend toward higher accuracy for death risk than adjudicated radiologic responses (hazard ratio for end of treatment by-model CMR of 0.123, 0.054, and 0.205 in ClinicalTrials.gov identifiers NCT01287741, NCT02500407, and NCT02257567, compared with, respectively, 0.226, 0.292, and 0.272 for CMR by the adjudicated responses). Furthermore, a radiologist review of the algorithm's assessments was conducted. The radiologist median review time was 1.38 minutes/assessment, and no statistically significant differences were observed in the level of agreement of the radiologist with the model's response compared with the level of agreement of the radiologist with the adjudicated responses. CONCLUSION These results suggest that the proposed method can be incorporated into radiologic response assessment workflows in cancer imaging for significant time savings and with performance similar to trained medical experts.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma
    Kumar, R.
    Xiu, Y.
    Zhuang, H. M.
    Alavi, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (02) : 357 - 363
  • [2] Neurolymphomatosis detected by 18F-fluorodeoxyglucose-positron emission tomography
    Hori, Yoshikazu
    Maruyama, Dai
    Maeshima, Akiko Miyagi
    Ida, Hanae
    Kurihara, Hiroaki
    Izutsu, Koji
    EJHAEM, 2020, 1 (01): : 19 - 20
  • [3] 18F-fluorodeoxyglucose-avid thyroid incidentalomas in patients with lymphoma
    Cohen, Tzeela
    Krausz, Yodphat
    Nissan, Avirarn
    Ben-Yehuda, Dina
    Klein, Martine
    Freund, Herbert R.
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2006, 8 (10): : 720 - 721
  • [4] Midtreatment 18F-Fluorodeoxyglucose Positron-Emission Tomography in Aggressive Non-Hodgkin Lymphoma
    Zinzani, Pier Luigi
    Gandolfi, Letizia
    Broccoli, Alessandro
    Argnani, Lisa
    Fanti, Stefano
    Pellegrini, Cinzia
    Stefoni, Vittorio
    Derenzini, Enrico
    Quirini, Federica
    Baccarani, Michele
    CANCER, 2011, 117 (05) : 1010 - 1018
  • [5] The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography
    Ozkol, Volkan
    Alper, Eray
    Aydin, Nesrin
    Ozkol, Hayriye Funda
    Topal, Naile Bolca
    Akpinar, Ali Tayyar
    NUCLEAR MEDICINE COMMUNICATIONS, 2010, 31 (02) : 128 - 136
  • [6] 18F-fluorodeoxyglucose-positron emission tomography:: A new explorative perspective
    Schirmer, M
    Calamia, KT
    Wenger, M
    Klauser, A
    Salvarani, C
    Moncayo, R
    EXPERIMENTAL GERONTOLOGY, 2003, 38 (04) : 463 - 470
  • [7] Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography
    Yap, CS
    Czernin, J
    Fishbein, MC
    Cameron, RB
    Schiepers, C
    Phelps, ME
    Weber, WA
    CHEST, 2006, 129 (02) : 393 - 401
  • [8] The Utility of 18-F-Fluorodeoxyglucose Positron Emission Tomography in Evaluation of Bone Marrow Involvement by Non-Hodgkin Lymphoma
    Muslimani, Alaa A.
    Farag, Hany L.
    Francis, Smitha
    Spiro, Timothy P.
    Chaudhry, Asif A.
    Chan, Vincent C.
    Taylor, Harris C.
    Daw, Hamed A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (05): : 409 - 412
  • [9] 18F-fluorodeoxyglucose-positron emission tomography imaging in idiopathic inflammatory myositis
    Harari, Olivier A.
    Al-Nahhas, Adil
    Jawad, Ali
    NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (09) : 838 - 840
  • [10] Incidental Breast Lesions Identified by 18F-Fluorodeoxyglucose-Positron Emission Tomography
    Alice Chung
    Heiko Schoder
    Michelle Sampson
    Monica Morrow
    Elisa Port
    Annals of Surgical Oncology, 2010, 17 : 2119 - 2125